Affordable Access

Tryptophan catabolism is dysregulated in leiomyomas

  • Chuang, Tsai-Der
  • Quintanilla, Derek
  • Boos, Drake
  • Khorram, Omid
Publication Date
Oct 01, 2021
eScholarship - University of California
External links


ObjectiveTo determine the expression and functional roles of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) in leiomyoma.DesignExperimental study.SettingAcademic research laboratory.Patient(s)Women undergoing hysterectomy for leiomyoma.Intervention(s)Blockade of IDO1 and TDO2.Main outcome measure(s)Expression of IDO1 and TDO2 in leiomyoma and the effects of their inhibitors on the extracellular matrix.Result(s)Leiomyoma expressed significantly higher levels of IDO1 and TDO2 messenger ribonucleic acid (mRNA; 60.3%, 35/58 pairs and 98.3%, 57/58 pairs, respectively) and protein (54%, 27/50 pairs and 92%, 46/50 pairs, respectively) as well as the enzyme activity marker kynurenine (78.3%, 36/46 pairs for IDO1/TDO2) compared with levels in matched myometrium. The expression of TDO2 but not IDO1 mRNA was significantly higher in fibroids from African American compared with that in Caucasian and Hispanic patients. The TDO2 but not the IDO1 protein and mRNA levels were more abundant in fibroids bearing the MED12 mutation compared with results in wild-type leiomyomas. Treatment of leiomyoma smooth muscle cell and myometrial smooth muscle cell spheroids with the TDO2 inhibitor 680C91 but not the IDO1 inhibitor epacadostat significantly repressed cell proliferation and the expression of collagen type I (COL1A1) and type III (COL3A1) in a dose-dependent manner; these effects were more pronounced in leiomyoma smooth muscle cells compared with myometrial smooth muscle cell spheroids.Conclusion(s)These results underscore the physiological significance of the tryptophan degradation pathway in the pathogenesis of leiomyomas and the potential utility of anti-TDO2 drugs for treatment of leiomyomas.

Report this publication


Seen <100 times